EAST LYME, Conn. Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced the addition of Paul Chew, MD, as its Chief Medical Officer (CMO). Dr. Chew also joins the Phesi Board of Directors, which was expanded in 2017 by the appointments of Annalisa Jenkins, MBBS, FRCP, and Steve Arlington, PhD. Phesi leverages the industry’s most comprehensive clinical trials database and predictive analytics tools to help trial sponsors make timely and informed decisions, and to expedite drug development. Dr. Chew and the distinguished Board will help guide the company as it continues to expand its work with global life sciences companies.
Read the full press release on Business Wire.